Sorafenib in Previously Treated Malignant Mesothelioma
The principal objective of the study is to investigate the effect of sorafenib on progression free survival (time until the cancer begins to grow again,) in patients with malignant mesothelioma who have had prior treatment with chemotherapy. Effectiveness of the drug will also be explored with PET scans before and during treatment.
Mesothelioma
DRUG: Sorafenib
Progression-free survival, 24 weeks
Response rate as assessed with CT scan, 2 months|Overall survival, Median|Change in FDG-PET avidity, 8 weeks
The principal objective of the study is to investigate the effect of sorafenib on progression free survival (time until the cancer begins to grow again,) in patients with malignant mesothelioma who have had prior treatment with chemotherapy. Effectiveness of the drug will also be explored with PET scans before and during treatment.